XML 30 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
Share-Based Compensation
9 Months Ended
Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Share-Based Compensation
Share-Based Compensation

In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “Plan”), which provides for grants of up to a maximum of 5.0 million shares of restricted stock, stock options, restricted stock units ("RSUs") and other equity-based awards. In June 2014, the Board of Directors approved, and in July 2014, our stockholders ratified, an increase of an additional 1.8 million shares of our common stock for issuance under the Plan, an increase of the maximum number of shares subject to stock options that may be awarded to any one participant under the Plan during any fiscal 12-month period from 1.0 million to 2.5 million shares, and an extension of the term of the Plan by ten years, to February 2025.  Directors, officers and other employees of the Company and its subsidiaries, as well as others performing services for the Company, are eligible for grants under the Plan.

During the three and nine months ended December 31, 2017, pre-tax share-based compensation costs charged against income were $2.2 million and $6.9 million, respectively, and the related income tax recognized was an expense of $0.1 million and a benefit of $1.4 million, respectively. During the three and nine months ended December 31, 2016, pre-tax share-based compensation costs charged against income were $2.4 million and $6.3 million, respectively, and the related income tax benefit recognized was $1.3 million and $2.5 million, respectively.

At December 31, 2017, there were $8.5 million of unrecognized compensation costs related to unvested share-based compensation arrangements under the Plan, based on management's estimate of the shares that will ultimately vest.  We expect to recognize such costs over a weighted-average period of 1.0 year.  The total fair value of options and RSUs vested during the nine months ended December 31, 2017 and 2016 was $6.8 million and $6.0 million, respectively.  For the nine months ended December 31, 2017 and 2016, we received cash from the exercise of stock options of $1.5 million and $3.4 million, respectively. For the nine months ended December 31, 2017 and 2016, we realized $1.1 million and $1.8 million, respectively, in tax benefits from the tax deductions resulting from RSU issuances and stock option exercises. At December 31, 2017, there were 2.2 million shares available for issuance under the Plan.

On May 8, 2017, the Compensation and Talent Management Committee of our Board of Directors granted 35,593 performance units, 54,773 RSUs and stock options to acquire 182,823 shares of our common stock to certain executive officers and employees under the Plan. The stock options were granted at an exercise price of $56.11 per share, which was equal to the closing price for our common stock on the date of the grant.
Pursuant to the Plan, each of the independent members of the Board of Directors received a grant of 2,564 RSUs on August 1, 2017. The RSUs are fully vested upon receipt of the award and will be settled by delivery to the director of one share of common stock of the Company for each vested RSU promptly following the earliest of the director's (i) death, (ii) disability or (iii) the six-month anniversary of the date on which the director's Board membership ceases for reasons other than death or disability.

Restricted Stock Units

RSUs granted to employees under the Plan generally vest in three years, primarily upon the attainment of certain time vesting thresholds, and, in the case of performance share units, may also be contingent on the attainment of certain performance goals of the Company, including revenue and earnings before income taxes, depreciation and amortization targets.  The RSUs provide for accelerated vesting if there is a change of control, as defined in the Plan.  The RSUs granted to employees generally vest either ratably over three years or in their entirety on the three-year anniversary of the date of the grant. Upon vesting, the units will be settled in shares of our common stock. Termination of employment prior to vesting will result in forfeiture of the RSUs, unless otherwise accelerated by the Compensation and Talent Management Committee or, in the case of RSUs granted in May 2017, subject to pro-rata vesting in the event of death, disability or retirement. The RSUs granted to directors vest immediately upon grant, and will be settled by delivery to the director of one share of common stock of the Company for each vested RSU promptly following the earliest of the director's (i) death, (ii) disability or (iii) the six-month anniversary of the date on which the director's Board membership ceases for reasons other than death or disability.

The fair value of the RSUs is determined using the closing price of our common stock on the date of the grant. The weighted-average grant-date fair value of RSUs granted during the nine months ended December 31, 2017 and 2016 was $55.61 and $55.44, respectively.

A summary of the Company's RSUs granted under the Plan is presented below:
 
 
 
RSUs
 
 
Shares
(in thousands)
 
Weighted-
Average
Grant-Date
Fair Value
Nine Months Ended December 31, 2016
 
 
 
 
Vested and nonvested at March 31, 2016
 
467.8

 
$
35.22

Granted
 
68.4

 
55.44

Vested and issued
 
(94.7
)
 
28.51

Forfeited
 
(91.4
)
 
41.71

Vested and nonvested at December 31, 2016
 
350.1

 
39.29

Vested at December 31, 2016
 
63.4

 
20.12

 
 
 

 
 

Nine Months Ended December 31, 2017
 
 
 
 
Vested and nonvested at March 31, 2017
 
350.1

 
$
39.29

Granted
 
105.8

 
55.61

Vested and issued
 
(53.3
)
 
34.30

Forfeited
 
(8.8
)
 
48.49

Vested and nonvested at December 31, 2017
 
393.8

 
44.14

Vested at December 31, 2017
 
90.5

 
29.88



Options

The Plan provides that the exercise price of options granted shall be no less than the fair market value of the Company's common stock on the date the options are granted.  Options granted have a term of no greater than ten years from the date of grant and vest in accordance with a schedule determined at the time the option is granted, generally three to five years.  The option awards provide for accelerated vesting in the event of a change in control, as defined in the Plan. Except in the case of death, disability or retirement, termination of employment prior to vesting will result in forfeiture of the unvested stock options. Vested stock options will remain exercisable by the employee after termination of employment, subject to the terms in the Plan.

The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions noted in the table below.  Expected volatilities are based on the historical volatility of our common stock and other factors, including the historical volatilities of comparable companies.  We use appropriate historical data, as well as current data, to estimate option exercise and employee termination behaviors.  Employees that are expected to exhibit similar exercise or termination behaviors are grouped together for the purposes of valuation.  The expected terms of the options granted are derived from our historical experience, management's estimates, and consideration of information derived from the public filings of companies similar to us, and represent the period of time that options granted are expected to be outstanding.  The risk-free rate represents the yield on U.S. Treasury bonds with a maturity equal to the expected term of the granted options.  

The weighted-average grant-date fair values of the options granted during the nine months ended December 31, 2017 and 2016 were $21.20 and $21.75, respectively.
 
 
Nine Months Ended December 31,
 
 
2017
 
2016
Expected volatility
 
35.2
%
 
37.8
%
Expected dividends
 
$

 
$

Expected term in years
 
6.0

 
6.0

Risk-free rate
 
2.2
%
 
1.7
%


A summary of option activity under the Plan is as follows:
 
 
 
 
Options
 
 
 
Shares
(in thousands)
 
Weighted-
Average
Exercise
Price
 
Weighted-
Average
Remaining
Contractual
Term (years)
 
Aggregate
Intrinsic
Value
(in thousands)
Nine Months Ended December 31, 2016
 
 
 
 
 
 
 
 
Outstanding at March 31, 2016
 
727.7

 
$
30.70

 
 
 
 
Granted
 
264.3

 
55.86

 
 
 
 
Exercised
 
(107.9
)
 
31.91

 
 
 
 
Forfeited or expired
 
(92.2
)
 
42.62

 
 
 
 
Outstanding at December 31, 2016
 
791.9

 
37.54

 
7.4
 
$
12,543

Exercisable at December 31, 2016
 
387.0

 
25.70

 
6.3
 
$
10,217

 
 
 
 
 
 
 
 
 
Nine Months Ended December 31, 2017
 
 

 
 

 
 
 
 

Outstanding at March 31, 2017
 
772.3

 
$
37.70

 
 
 
 
Granted
 
182.8

 
56.11

 
 
 
 
Exercised
 
(51.0
)
 
28.76

 
 
 
 
Forfeited or expired
 
(22.1
)
 
48.15

 
 
 
 
Outstanding at December 31, 2017
 
882.0

 
41.77

 
7.2
 
$
7,019

Exercisable at December 31, 2017
 
502.9

 
32.50

 
6.1
 
$
6,884



The aggregate intrinsic value of options exercised in the nine months ended December 31, 2017 was $1.2 million.